Please ensure Javascript is enabled for purposes of website accessibility

How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?

By Brian Orelli, PhD – Apr 3, 2018 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A battle for transthyretin amyloidosis patients is brewing.

Last week, Pfizer (PFE -0.91%) released positive results from its ATTR-ACT phase 3 trial testing tafamidis for patients with a rare disease called transthyretin (TTR) amyloidosis cardiomyopathy, sending shares of fellow TTR-drug makers Alnylam Pharmaceuticals (ALNY -4.41%) and Ionis Pharmaceuticals (IONS -0.11%) down 22% and 8.3% over the following two trading days, respectively. Akcea Therapeutics (AKCA), which recently licensed rights to a share in Ionis' drug, inotersen, as well as a follow-on compound, also fell 12.2% over that time frame.

Barry Greene

Barry Greene. Image source: Alnylam.

But if you listened to Alnylam's president Barry Greene on the biotech's fourth-quarter earnings call, the ATTR-ACT trial was a heads-I-win-tails-you-lose kind of result for Alnylam:

If ATTR-ACT is, in fact, a positive, it's further confirmation that modulation of TTR is beneficial for these patients, and as you know, including cardiomyopathy subpopulation, we've shown a reversal of disease in the majority of patients. And if ATTR-ACT is negative, then it demonstrates sort of the lack of efficacy we've already seen with tafamidis. So I think, either way, we're in good shape for patisiran.

The new kids are winning in neurology

While Greene is obviously presenting the best-case scenario for Alnylam, there's definitely some validity to his argument.

Before ATTR-ACT, Pfizer's tafamidis hadn't exactly posted the best data for the neurological symptoms of TTR amyloidosis (ATTR). In 2012, the Food and Drug Administration (FDA) rejected a marketing application for tafamidis because the clinical trial missed its primary endpoints of improving patients' Neuropathy Impairment Score-Lower Limb (NIS-LL) and a quality of life measurement. European regulators, who are typically more relaxed about efficacy data for rare diseases, approved the drug in Europe, where it goes by the band name Vyndaqel, based on a secondary endpoint of improving the measurements in evaluable patients.

Neither Alnylam's patisiran nor Ionis and Akceas' inotersen had any problems showing efficacy in their pivotal trials. After 18 months of treatment, patisiran posted a 34-point benefit on the modified Neurologic Impairment Score (mNIS+7) scale, which measures disease activity, compared to those receiving a placebo. The trial for inotersen showed a 19.7-point benefit over a placebo after 15 months of treatment.

Female doctor talking to white-haired male patient

Image source: Getty Images.

Symptoms beget outcomes in cardiology?

ATTR is caused by the TTR protein aggregating in different organs. The NIS scores focus on neurological symptoms, but TTR can also become deposited in the cardiovascular system, and many patients have both issues.

Pfizer's ATTR-ACT trial specifically looked at ATTR patients with cardiomyopathy caused by the TTR protein aggregating in the cardiovascular system. Pfizer didn't report any numbers last week, electing to save the data for a medical meeting, but the pharma giant said patients taking tafamidis had reduced mortality compared to those taking placebo over the 30-month trial. The drug also reduced cardiovascular-related hospitalizations compared to a placebo.

Outcomes data -- especially survival data -- is always better than data that just shows reduction of symptoms, but patisiran and inotersen appear to work so well that doctors will likely view the symptoms data for patisiran and inotersen and expect that they'll both produce good outcomes for patients even if Alnylam and Ionis don't have the data to prove it yet. In addition to the aforementioned neurological data, Alnylam also has data from the 56% of patients in its pivotal trial who also had cardiac symptoms that shows patisiran improved cardiac structure and function and reduced levels of a cardiac stress biomarker called NT-proBNP.

Investor takeaway

Because there hasn't been a treatment for ATTR, the disease is highly underdiagnosed; Pfizer thinks less than 1% of patients with cardiomyopathy have actually been diagnosed.

Even if the ATTR-ACT data results in tafamidis taking market share from patisiran and inotersen, Alnylam, Ionis, and Akcea might not lose that much -- if any -- revenue because having Pfizer using its marketing muscle to promote the ATTR-ACT data will likely result in more patients being diagnosed with the disease. In the end, the smaller biotechs might end up getting a smaller piece of a much larger pie than if they were out there promoting their drugs on their own.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals and Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.76 (-0.91%) $0.40
Ionis Pharmaceuticals, Inc. Stock Quote
Ionis Pharmaceuticals, Inc.
IONS
$44.23 (-0.11%) $0.05
Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
ALNY
$200.16 (-4.41%) $-9.23
Akcea Therapeutics, Inc. Stock Quote
Akcea Therapeutics, Inc.
AKCA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.